CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Receives Average Rating of “Moderate Buy” from Analysts

CAMP4 Therapeutics Corporation (NASDAQ:CAMP) has earned a consensus recommendation of “Moderate Buy” from the eight brokerages that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $10.17.

A number of research analysts have recently weighed in on CAMP shares. Weiss Ratings lowered CAMP4 Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday. Chardan Capital decreased their price target on CAMP4 Therapeutics from $6.50 to $6.00 and set a “buy” rating for the company in a report on Tuesday, September 29th. JPMorgan Chase & Co. upgraded shares of CAMP4 Therapeutics from a “neutral” rating to an “overweight” rating and upped their target price for the stock from $5.00 to $9.00 in a research note on Tuesday, June 16th. UBS Group set a $15.00 target price on shares of CAMP4 Therapeutics in a report on Friday, August 14th. Finally, Zacks Research upgraded shares of CAMP4 Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday, August 17th.

Insider Buying and Selling

In other CAMP4 Therapeutics news, CFO Kelly Gold bought 10,000 shares of the firm’s stock in a transaction dated Monday, August 31st. The stock was purchased at an average cost of $3.96 per share, with a total value of $39,600.00. Following the transaction, the chief financial officer directly owned 10,000 shares in the company, valued at $39,600. This trade represents a ∞ increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Richard A. Young bought 16,378 shares of the stock in a transaction dated Monday, August 3rd. The shares were acquired at an average price of $1.65 per share, for a total transaction of $27,023.70. Following the completion of the purchase, the director directly owned 186,388 shares in the company, valued at approximately $307,540.20. This trade represents a 9.63% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last three months, insiders have acquired 46,031 shares of company stock worth $99,051 and have sold 593,613 shares worth $2,504,037. 21.69% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On CAMP4 Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. Bank of America Corp DE purchased a new position in CAMP4 Therapeutics in the second quarter valued at about $78,000. Trails Edge Capital Partners LP purchased a new stake in shares of CAMP4 Therapeutics during the 2nd quarter worth approximately $8,446,935. Jupiter Topco LLC bought a new stake in shares of CAMP4 Therapeutics in the 2nd quarter worth approximately $27,581,000. 5AM Venture Management LLC bought a new stake in shares of CAMP4 Therapeutics in the 2nd quarter worth approximately $25,647,928. Finally, BlackRock Inc. purchased a new position in CAMP4 Therapeutics in the second quarter valued at approximately $7,185,000.

CAMP4 Therapeutics Price Performance

Shares of NASDAQ:CAMP opened at $4.00 on Wednesday. CAMP4 Therapeutics has a twelve month low of $2.86 and a twelve month high of $7.75. The stock’s 50 day moving average is $4.16 and its 200-day moving average is $4.26. The firm has a market capitalization of $251 million, a price-to-earnings ratio of -1.72 and a beta of 0.27.

CAMP4 Therapeutics (NASDAQ:CAMP) last posted its quarterly earnings results on Thursday, August 13th. The Wireless communications provider reported ($0.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.34). The business had revenue of $1.78 million during the quarter. CAMP4 Therapeutics had a negative net margin of 2,543.74% and a negative return on equity of 252.79%. Equities research analysts anticipate that CAMP4 Therapeutics will post -0.57 earnings per share for the current fiscal year.

CAMP4 Therapeutics Company Profile

CAMP4 Therapeutics Corporation is a clinical-stage biotechnology company focused on developing RNA-based medicines for genetic diseases caused by insufficient production of essential proteins. The company’s approach is designed to increase expression of a patient’s existing genes rather than replace or edit them.

CAMP4 uses its RegRNA platform to identify regulatory elements in messenger RNA and develop RNA activators, including small activating RNAs, that may stimulate production of targeted proteins.